Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $360 from $408 and keeps an Equal Weight rating on the shares. Q4 revenue was preannounced and management reiterated 2026 TTR sales guidance signaling continued confidence in the launch despite near-term headwinds, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target lowered to $451 from $491 at Bernstein
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/13/2026, According to Top Analysts
- Alnylam price target lowered to $425 from $475 at Chardan
- Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions
- Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating